Statins, HIV, and CVD.

Slides:



Advertisements
Similar presentations
2 New HIV diagnoses and number of persons accessing HIV care in the United Kingdom: 2014.
Advertisements

I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Upfront Combination Therapy vs Step-Up Approach for PAH:
HIV-Associated Weight Loss and Wasting
Diabetic Dyslipidemia in Practice
A Review of the Critical Role of Imaging in Primary Liver Malignancy
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
An Endocrinology Clinic in Dyslipidemia
HIV Testing:.
Tailoring Statin Therapy in Women
Case 53-year-old Black Man
HCV Care in Unique Patient Populations
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Select Topics in Cardiovascular Medicine
Is Your Patient Engaged in Care
Statins and the Elderly Patient
Managing Comorbidities in Patients With Rheumatoid Arthritis
Statin Selection in Special Patient Populations: A Case Challenge
PrEP in Women: Unique Considerations and Strategies
Understanding Statin Metabolism
Chronic Idiopathic Urticaria
Tailoring Hemophilia Prophylaxis Therapy
Follow-Up of the Patient After PE
Statin Class in Session
Diabetes Increases Risk of CVD
Assessing the State of Statin Therapy
An Update on PCSK9 Inhibitors
Precision Management of RA and Comorbidities
A Pharmacist's Guide to PCSK9 Inhibitors:
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
Statins and Glucose Metabolism: Are All Agents Alike?
Statin Class in Session
Agenda. Agenda HIV in the United States HIV in the United States (cont)
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
Is it Time for a Paradigm Change in HIV Management?
CV Risk Doesn't End in the Cath Lab
Personalizing Statin Therapy in Patients With HIV
A Journal Club on Lipid Management:
Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
Improving Appropriate Access to PCSK9 Inhibitors
From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP
Statins and HIV:.
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
HIV Treatment: What Can You Do to Get and Keep Patients in Care?
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Personalized Therapy in Relapsed or Refractory CLL
CV Risk Doesn't End in the Cath Lab
Statins, HIV, and CVD.
Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Advancing Patient Care in RA
SLE and Cardiovascular Risk
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Updates From ACC.
Optimizing Joint Health in Hemophilia
Healthy With HIV.
Reducing Risk for CV Outcomes
Improving Overall Health
New Lipid-Lowering Guidelines
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Merging the Art and Science of Managing nOH in Clinical Practice
Lipids, the Heart, and the Kidney
Presentation transcript:

Statins, HIV, and CVD

Program Themes

Background

Causes of Increased CVD Risk in Persons Infected With HIV

Changes in Causes of Death for HIV-Diagnosed New Yorkers

Viral and ART Factors Ingredients in an "Atherogenic Soup"

40-Year-Old Man Presents for HIV Care

Top Priority Initiate ART

Contemporary ART More Lipid Neutral

Case Study: 1 Year Later

Follow-Up Lipid Profile

Mean Changes in Blood Lipid Levels for 50 Seroconverters Initiating HAART

CVD Risk in Patients With HIV Infection

Assessment of CV Risk in the HIV-Infected Patient

How Is HIV Unique?

HIV-Specific Lipid Issues

Use of Statins With Protease Inhibitors

National Lipid Association Recommendations

Impact of Statins on Atherosclerosis in HIV

INTREPID

REPRIEVE Trial Design

Concluding Remarks

Abbreviations

Abbreviations (cont)